Targeting β-catenin dependent Wnt signaling via peptidomimetic inhibitors in murine chondrocytes and OA cartilage by Held, A. et al.
VU Research Portal
Targeting -catenin dependent Wnt signaling via peptidomimetic inhibitors in murine
chondrocytes and OA cartilage
Held, A.; Glas, A.; Dietrich, L.; Bollmann, M.; Brandstädter, K.; Grossmann, T. N.;




DOI (link to publisher)
10.1016/j.joca.2018.02.908
document version
Publisher's PDF, also known as Version of record
document license
Article 25fa Dutch Copyright Act
Link to publication in VU Research Portal
citation for published version (APA)
Held, A., Glas, A., Dietrich, L., Bollmann, M., Brandstädter, K., Grossmann, T. N., Lohmann, C. H., Pap, T., &
Bertrand, J. (2018). Targeting -catenin dependent Wnt signaling via peptidomimetic inhibitors in murine
chondrocytes and OA cartilage. Osteoarthritis and Cartilage, 26(6), 818-823.
https://doi.org/10.1016/j.joca.2018.02.908
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl
Download date: 27. May. 2021
Osteoarthritis and Cartilage 26 (2018) 818e823Brief ReportTargeting b-catenin dependent Wnt signaling via peptidomimetic
inhibitors in murine chondrocytes and OA cartilage
A. Held y, A. Glas z, L. Dietrich z, M. Bollmann y, K. Brandst€adter x, T.N. Grossmann z k,
C.H. Lohmann y, T. Pap ¶, J. Bertrand y *
y Department of Orthopaedic Surgery, Otto-von-Guericke University, Magdeburg, Germany
z Chemical Genomics Centre of the Max-Planck Society, Dortmund, Germany
x Institute of Forensic Medicine, University Hospital Halle, Remote Office Magdeburg, Halle (Saale), Magdeburg, Germany
k Department of Chemistry and Pharmaceutical Science, VU University Amsterdam, Amsterdam, The Netherlands
¶ Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germanya r t i c l e i n f o
Article history:
Received 5 December 2017







Wnt3a* Address correspondence and reprint requests to
Orthopaedic Surgery, Otto-von-Guericke University M
39120 Magdeburg, Germany.
E-mail address: jessica.bertrand@med.ovgu.de (J. B
https://doi.org/10.1016/j.joca.2018.02.908
1063-4584/© 2018 Published by Elsevier Ltd on behas u m m a r y
Objective: The canonical Wnt signaling pathway has been shown to be involved in regulating chon-
drocyte hypertrophic differentiation during Osteoarthritis (OA). The aim of this study was to test the
therapeutic potential of two stapled peptide canonical Wnt inhibitors e SAH-Bcl9 and StAx-35R e in
preventing Wnt induced cartilage changes in OA.
Methods: Primary neonatal murine chondrocytes and cartilage explants from OA patients undergoing
total joint replacement for knee OA, were used for microscopy to determine matrix and cell penetrating
capacity of fluorescein isothiocyanate FITC-tagged SAH-Bcl9 and StAx-35R peptides. T cell factor/
lymphoid enhancer-binding factor (TCF/LEF) reporter assays were used to monitor the inhibition of
Wnt3a induced b-catenin signaling by each peptide. Changes in chondrocyte phenotypic marker gene
expression were analyzed by qRT PCR.
Results: Both peptides localized intercellular in primary murine chondrocytes and cartilage explants.
They inhibited Wnt3a induced TCF/LEF promoter activity in primary murine chondrocytes. Both in-
hibitors did not rescue Wnt3a altered expression of chondrocyte phenotypic genes (Sox9, Col2a1, Acan)
and hypertrophy marker gene (Col10a1) at high doses (100 ng/ml). Upon application of 10 ng/ml Wnt3a,
StAx-35R partially reversed the Wnt effect on Sox9 and Col2a1 gene expression. Both peptides, however,
reversed the downregulation of SOX9 and aggrecan (ACAN), and decrease of COL10A1 gene expression in
preserved human OA cartilage explants.
Conclusion: These data indicate that blockade of canonical Wnt signaling might be a therapeutic strategy
to treat early OA cases and protect further cartilage degradation by preventing chondrocyte hypertrophic
differentiation.
© 2018 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
Osteoarthritis (OA) is characterized by progressive destruction
of articular cartilage. One central pathologic feature is the pheno-
typic shift of chondrocytes from resting towards hypertrophic.
Among others, this shift is triggered by activation of canonical Wnt/
b-catenin signaling. Enhanced expression of Wnt signaling com-
ponents has been shown in various OA systems1,2. Activation of the
canonical pathway alters the characteristic expression pattern of: J. Bertrand, Department of
agdeburg, Leipziger Str. 44,
ertrand).
lf of Osteoarthritis Research Societchondrocytes, resulting in decreased type II collagen (COL2A1),
aggrecan (ACAN), SOX9, and in increased type X collagen
(COL10A1) expression, and therewith promoting cell de-differen-
tiation1,3. Conclusively, therapeutic inhibition of canonical Wnt/b-
catenin signaling to maintain chondrocyte phenotypic stability and
therewith cartilage homeostasis is desirable for OA treatment.
In absence of Wnt signaling, cytosolic b-catenin is degraded.
Upon Wnt ligand binding to its receptors Frizzled (Fz) and low-
density lipoprotein-related receptor protein 5 and 6 (LRP5/6) the
b-catenin gets stabilized, accumulates in the cytoplasma and
translocates into the nucleus. Here, b-catenin binds T cell factor/
lymphoid enhancer-binding factor (TCF/LEF) and mobilizes other
co-activators such as the B-cell lymphoma protein (Bcl9) to induce
gene transcription4.y International.
A. Held et al. / Osteoarthritis and Cartilage 26 (2018) 818e823 819Distinct regulation of the canonical Wnt signaling is required to
prevent the development of various diseases including OA and
cancer. Therefore, siRNAs, antibodies and small molecule inhibitors
are under continuous investigation to interfere with Wnt signal
transduction5,6. Two small molecule inhibitors, the stapled pep-
tides StAx-35R (stapled b-catenin binding domain of Axin) and
SAH-Bcl9 (stapled peptide derived from the Bcl9 homology
domain-2), have been established to inhibit b-catenin transcrip-
tional activity and thereby canonical Wnt signaling mediated tu-
mor growth in cancer7,8. Both inhibitors of canonical Wnt signaling
mimic binding domains that directly interact with b-catenin and
disrupt b-catenin transcriptional function. We tested SAH-Bcl9 and
StAx-35R for their ability to prevent canonical Wnt signaling
induced hypertrophic differentiation of chondrocytes in OA.
Methods
Chondrocyte isolation and cartilage explants
Murine chondrocytes of knee cartilage were isolated from 5 to 8
days old neonatal C57Bl/6 mice as described9. All experiments were
performed using freshly isolated chondrocytes, which were
cultured in Dulbecco's Modified Eagle's Medium (DMEM) con-
taining 10% fetal bovine serum (FBS), 1 mM sodium pyruvate and
penicillin (10.000 U/ml)/streptomycin (10 mg/ml).
Human OA articular cartilage was obtained from patients un-
dergoing joint replacement for knee OA after obtained consent
(ethics number: 23/16). Full thickness samples were dissected from
preserved and OA areas of articular cartilage of OA patients by
macroscopic distinction between loaded (OA) and non-loaded
(preserved) cartilage areas. Explants were kept in culture medium
(see above) without further treatment for 48 h until application of
Wnt inhibitors.
Peptide synthesis and characterization
Peptides were synthesized as recently reported and described in
detail in Supplemental Material. Fluorescein isothiocyanate FITC-
tagged inhibitors were applied to cells, preserved or OA cartilage
explants for microscopic analysis of cell penetration. Acetylated
(Ac-) SAH-Bcl9 and StAx-35R were used for in vitro cell culture and
explant experiments for subsequent gene expression analysis. As
Ac-SAH-Bcl9 and Ac-StAx-35R were solved in dimethylsulfoxide
(DMSO), DMSO has been introduced as vehicle control in the
respective experiments.
RNA extraction, cDNA synthesis, real-time RT-PCR
Total RNA was extracted from cells and cartilage explants using
TRIzol reagent (Invitrogen). 1 ng of total RNA from each sample was
reverse transcribed using High-Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems) using oligo dT primers. Quantitative
polymerase chain reaction (PCR) was performed with SYBR Green I
(SG) asymmetrical cyanine dye (SYBR) green using Applied Bio-
systems™ PRISM 7900HT (Thermo Scientific). Primer sequences
are listed in Suppl. Tables 2 and 3. Absolute quantification was
carried out using standard curves. Target gene expression was
normalized to Glyceraldehyde-3-Phosphate Dehydrogenase
(GAPDH).
Transfection and luciferase reporter assay
Subconfluent chondrocytes were co-transfected with Super
8XTOPFlash TCF/LEF-firefly luciferase reporter vector and cyto-
megalovirus CMV-Renilla luciferase vector (ratio 1:1, 0.75 mg pDNA/well) using jetPRIME (Polypus). Transfection efficiency was deter-
mined by microscopic counting of green fluorescent protein (GFP)
positive cells in a separate well as transfection control (approxi-
mately 30% in each experiment). 24 h after transfection, cells were
pre-incubated with Ac-SAH-Bcl9, Ac-StAx-35R or vehicle for 1 h
before treatment for 24 hwith 100 ng/ml rmWnt3a (R&D Systems).
Luciferase activity wasmeasured using the Dual Luciferase Reporter
Assay System (Promega) and GloMax 20/20 Luminometer (Prom-
ega), Infinite® 200 Pro (Tecan) spectrometer. Firefly luciferase ac-
tivitywas normalized to Renilla luciferase activity and to the vehicle
control.
Microscopy of FITC-tagged peptides
To investigate intracellular penetration of peptides, murine
chondrocytes were incubated with 10 mM FITC-SAH-Bcl9 or FITC-
StAx-35R for 24 h. Afterwards the cells were washed with phos-
phate buffered saline (PBS) and fixed with 4% paraformaldehyde.
Localization was determined by confocal fluorescence microscopy
(Zeiss LSM 700 confocal microscope). 40,6-Diamidin-2-phenylindol
(DAPI) was used for nuclear staining. Preserved or OA human
cartilage explants were treated with 10 mM FITC-SAH-Bcl9/FITC-
StAx-35R for 24 h. Afterwards the explants were washed, fixed
with Tissue Tek® and directly frozen in liquid nitrogen. Sections
were fixed in acetone-methanol, subsequently washed and stained
with Roti®-Mount FluorCare DAPI (Roth).
b-Catenin immunofluorescence
Paraffin sections from OA cartilage were rehydrated. For antigen
retrieval sections were pretreated with 0.02% HCl and then incu-
bated with pepsin (0.25 mg/ml in 0.02% HCl) for 45 min at 37C.
Free epitopes were blocked with 4% bovine serum albumin (BSA) in
PBS for 1 h at RT. Cartilage sections were stained with primary
antibody against b-catenin (1:70, Cell signaling #9562). Alexa
Fluor® 555 (Thermo Scientific) was applied as secondary antibody.
Sections were fixed with Roti®-Mount FluorCare DAPI.
Statistics
All data were presented as mean ± SEM. Data were analyzed by
one-way analysis of variance (ANOVA) following a Least Significant
Difference-Bonferroni Test (LSD) test as post-hoc test in case of a
significant ANOVA result. Data analyses were performed using
PASW Statistics 24 (SPSS, Chicago, IL, USA). Statistical significance
was determined at level of P < 0.05. *P < 0.05; **P  0.01,
***P  0.001.
Results
Wnt inhibitors reduced Wnt3a induced b-catenin reporter activity
and modified chondrocyte marker gene expression in primary
murine chondrocytes
Confocal fluorescence microscopy confirmed intracellular
localization of both, FITC-SAH-Bcl9 and -StAx-35R, peptides
[Fig. 1(A)]. To evaluate the dose-dependent inhibitory capacity of
100 nM, 5 mM, 10 mM and 15 mM Ac-SAH-Bcl9 or -StAx-35R, we
activated the TOPFlash canonical Wnt reporter in primary chon-
drocytes using 100 ng/ml Wnt3a [Fig. 1(B)]. Activation of this TCF/
LEF reporter assay was confirmed using 10 and 100 ng/ml Wnt3a
(Suppl. Fig. 1). Treatment with 10 mM inhibitor upon stimulation
with 100 ng/mlWnt3a resulted in a significant reduction of TCF/LEF
promoter activity (F ¼ 3.94, P < 0.05) of 57.8% for Ac-SAH-Bcl9
(mean ± SEM: 0.42 ± 0.24, P ¼ 0.03) and 74.2% for Ac-StAx-35R
Fig. 1. Wnt inhibitors reduced Wnt3a induced b-catenin reporter activity and modified chondrocyte marker gene expression in primary murine chondrocytes. Confocal
microscopy confirmed cytosolic localization of FITC-tagged SAH-Bcl9 and StAx-35R peptides (maximum intensity of z stacks, scale bar ¼ 10 mM, nucleus staining: DAPI (blue), A). In
comparison to vehicle and Wnt3a (100 ng/ml) treated chondrocytes, application of Ac-SAH-Bcl9 or Ac-StAx-35R instead of the vehicle resulted in a dose-dependent inhibition with
10 mM as maximum inhibitory concentration for both peptides (n ¼ 5 independent experiments, normalized to vehicle þ 100 ng/ml Wnt3a, ANOVA: F ¼ 3.94, P  0.001, B).
Treatment with Ac-SAH-Bcl9 did not rescue Wnt3a modulated gene expression e independently of the applied Wnt3a concentration (100 ng/ml n ¼ 4, C; 10 ng/ml n ¼ 3, D). Ac-
StAx-35R treatment reversed Wnt3a down-regulated Sox9 and Col2a1 gene expression at the lower Wnt3a concentration (D).
A. Held et al. / Osteoarthritis and Cartilage 26 (2018) 818e823820(0.26 ± 0.16, P  0.001), which was not further reduced with the
higher inhibitor concentration of 15 mM (SAH-Bcl9 0.45 ± 0.24,
P¼ 0.04; StAx-35R 0.32 ± 0.15, P 0.001). Hence, we applied 10 mM
inhibitor for all following experiments.
As both low (10 ng/ml) and high (100 ng/ml) dosages of Wnt3a
were able to induce b-catenin reporter activity, both concentra-
tions were tested regarding their effect on chondrocyte pheno-
typic marker gene expression. Wnt3a mediated stimulation of
canonical Wnt signaling or constitutively active b-cateninresulted in increased expression of chondrocyte hypertrophy
genes (e.g., Col10a1) and down-regulation of phenotypic genes
(e.g., Sox9, Col2a1, Acan)1,3,10. We also found that treatment with
100 ng/ml Wnt3a resulted in a down-regulation of Sox9 (vehicle
vs vehicle þ 100 ng/ml Wnt3a: 1.0 ± 0.14 vs 0.18 ± 0.17,
P  0.001), Acan (1.0 ± 0.10 vs 0.27 ± 0.12, P ¼ 0.0001) and Col2a1
(1.0 ± 0.09 vs 0.40 ± 0.12, P  0.001) [Fig. 1(C)]. Col10a1 gene
expression was upregulated upon treatment with 100 ng/ml
Wnt3a (Suppl. Fig. 2, vehicle vs 100 ng/ml Wnt3a: 1.0 ± 0.091 vs
A. Held et al. / Osteoarthritis and Cartilage 26 (2018) 818e823 8212.407 ± 0.794, P ¼ 0.043). Although chondrocytes were incubated
with Ac-SAH-Bcl9 or Ac-StAx-35R prior to Wnt3a stimulation,
inhibitors were not able to rescue 100 ng/ml Wnt3a modified
gene expression.Fig. 2. Wnt inhibitors protected the chondrocyte phenotype in human preserved OA car
e Alexa 555 (red), nucleus staining: DAPI (blue), scale bar ¼ 200 mm, A). FITC-tagged SAH
treatment as shown by microscopy of cartilage explants (scale bar ¼ 200 mm, B). qRT-PC
expression in preserved cartilage (n ¼ 6 patients, C) upon 24 h treatment with b-catenin/W
(n ¼ 3 patients, D).With the lower dosage of 10 ng/ml Wnt3a a similar down-
regulation of Sox9 (vehicle vs vehicleþ 100 ng/mlWnt3a: 1.0 ± 0.11
vs 0.48 ± 0.12, P¼ 0.003), Acan (1.0 ± 0.09 vs 0.44 ± 0.12, P 0.001)
and Col2a1 (1.0 ± 0.11 vs 0.52 ± 0.14, P ¼ 0.012) expression wastilage. Increasing b-catenin staining was observed with increasing OA grade (b-catenin
-Bcl9 and StAx-35R can penetrate into preserved and OA cartilage without any pre-
R analysis revealed significantly increased SOX9, ACAN and decreased COL10A1 gene
nt signaling inhibitors, which was not present in highly damaged OA cartilage samples
A. Held et al. / Osteoarthritis and Cartilage 26 (2018) 818e823822observed. Col10a1 gene expression upon stimulationwith 10 ng/ml
Wnt3a remained unchanged [Fig. 1(D); Suppl. Fig. 2]. Treatment
with Ac-SAH-Bcl9 did not reverse the Wnt-induced effect on
anabolic marker gene expression. Interestingly, treatment with Ac-
StAx-35R partially inhibited the effect of 10 ng/ml Wnt3a on Sox9
(vehicle vs Wnt3a þ StAx-35R: 1.0 ± 0.11 vs 0.73 ± 0.19, P ¼ 0.23)
and Col2a1 (vehicle vs Wnt3a þ StAx-35R: 1.0 ± 0.11 vs 0.77 ± 0.19,
P ¼ 0.32) gene expression. This finding gave rise to the assumption
that the inhibitors might be able to inhibit the phenotypic shift of
chondrocytes in OA. Therefore we used an ex vivo cartilage culture
model of OA, with disease dependent activation of canonical Wnt
signaling.
Wnt inhibitors protected the chondrocyte phenotype in human
preserved OA cartilage
It has been shown that b-catenin gets stabilized in OA cartilage
and increases upon disease progression1,10. To test whether b-cat-
enin as prominent effector of canonical Wnt signaling is present in
our experimental setting, we stained for this protein. We observed
an increased b-catenin staining with increasing OA grade, which
corroborates the activation of canonicalWnt signaling in human OA
cartilage [Fig. 2(A)].
Thus, we used preserved and OA lesion cartilage explants iso-
lated from OA knees and incubated these with FITC-tagged pep-
tides. Again, fluorescence microscopy proved the ability of both e
SAH-Bcl9 and StAx-35R e to penetrate into preserved as well as
OA cartilage [Fig. 2(B)]. Intriguingly, incubationwith 10 mMAc-SAH-
Bcl9 or Ac-StAx-25R for 24 h resulted in significant up-regulation of
SOX9 (vehicle vs Ac-SAH-Bcl9: 1.0 ± 0.42 vs 3.02 ± 0.40, P ¼ 0.001;
vehicle vs Ac-StAx-35R: 1.0 ± 0.42 vs 2.22 ± 0.38, P ¼ 0.037) and
ACAN (vehicle vs Ac-SAH-Bcl9: 1.0 ± 0.38 vs 2.51 ± 0.39, P ¼ 0.009;
vehicle vs Ac-StAx-35R: 1.0 ± 0.38 vs 2.15 ± 0.41, P ¼ 0.048) and
down-regulation of COL10A1 (vehicle vs Ac-SAH-Bcl9: 1.0 ± 0.08 vs
0.43 ± 0.08, P ¼ 0.001; vehicle vs Ac-StAx-35R: 1.0 ± 0.08 vs
0.56 ± 0.06, P ¼ 0.01) gene expression in preserved cartilage
[Fig. 2(C)].However, in OA cartilage this effect was not observed
[Fig. 2(D)].
Discussion
As treatment of OA is frequently symptomatic, using e.g., non-
steroidal anti-inflammatory drugs (NSAIDs) or intraarticular ste-
roids, and is mostly resulting at end-stage in total joint re-
placements, a treatment to prevent chondrocyte differentiation
during OA is desirable11. Consistently with other studies (e.g.1,2), we
have shown that canonical Wnt signaling is activated with
increasing OA disease severity [Fig. 2(A)], assuming that blockade of
this signaling cascade with small inhibitors prevents disease
progression.
We tested SAH-Bcl9 and StAx-35R for their therapeutic potential
in OA as they are already established for cancer treatment. Both
inhibitors penetrated into primary chondrocytes [Fig. 1(A)] and
cartilage explants [Fig. 2(B)]. They showed a dose-dependent in-
hibition of Wnt3a induced b-catenin reporter activity, exhibiting a
half maximal inhibition at 10 mM [Fig. 1(B)].
However, only the use of 10 ng/ml Wnt3a resulted in a chon-
droprotective effect upon StAx-35R treatment, with regard to Sox9
and Col2a1 expression [Fig. 1(D)]. The minor inhibitory effect on
Wnt3a modulated gene expression in isolated chondrocytes might
be attributed to the complexity of Wnt signaling. It has been shown
that inhibition or over-activation of canonical Wnt signaling results
in OA-like changes of articular cartilage and loss of the chondrocyte
phenotype10,12. Moreover, Wnt3a is not the only Wnt ligand which
expression is increased in OA chondrocytes2 and it can also activatenon-canonical signaling pathways3. This indicates that a delicate
balance inWnt signaling is needed to keep chondrocyte phenotypic
stability.
Further, heparan sulfate proteoglycans in the extracellular ma-
trix (ECM) seem to modulateWnt signaling by bindingWnt ligands
and facilitating ligandereceptor interactions13,14, thereby regu-
lating cell sensitivity. Hence, several factors affect Wnt signal
transduction, isolated chondrocytes might respond differently to
external stimuli than they would respond in vivo.
Blockade of canonical Wnt signaling by SAH-Bcl9 and StAx-35R
inhibited chondrocyte phenotypic shift in preserved cartilage
resulting in increased SOX9 and ACAN, and decreased COL10A1
gene expression [Fig. 2(C)]. In OA lesion cartilage theWnt inhibitors
had no effect. We hypothesize that OA lesion cartilage does not
contain enough viable chondrocytes to be targeted by the inhibitors
and to revert the already made changes to the chondrocyte
phenotype, as apoptosis of chondrocytes is increasing with OA
progression15.
The findings of this study give rise to a potential new thera-
peutic approach using peptidomimetic canonical Wnt inhibitors in
treatment of early OA.
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